Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

NTRA

Natera Inc

Feb 13 • 04:00PM ET

206.23

-1.61 -0.77 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VBK VXF IBB IWP IWF IWR XBI VHT

Index	-	P/E	-	EPS (ttm)	-2.28	Insider Own	4.81%	Shs Outstand	137.53M	Perf Week	1.57%
Market Cap	28.53B	Forward P/E	-	EPS next Y	-1.91	Insider Trans	-11.53%	Shs Float	131.67M	Perf Month	-13.78%
Enterprise Value	27.68B	PEG	-	EPS next Q	-0.51	Inst Own	93.71%	Short Float	2.58%	Perf Quarter	-1.56%
Income	-309.19M	P/S	13.48	EPS this Y	-56.68%	Inst Trans	0.15%	Short Ratio	2.64	Perf Half Y	30.16%
Sales	2.12B	P/B	22.65	EPS next Y	20.39%	ROA	-18.12%	Short Interest	3.40M	Perf YTD	-9.98%
Book/sh	9.10	P/C	27.36	EPS next 5Y	46.31%	ROE	-29.02%	52W High	256.36 -19.55%	Perf Year	20.79%
Cash/sh	7.54	P/FCF	268.96	EPS past 3/5Y	33.57% 3.18%	ROIC	-22.79%	52W Low	125.38 64.48%	Perf 3Y	382.97%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.47% 41.20%	Gross Margin	63.66%	Volatility	3.77% 4.14%	Perf 5Y	65.83%
Dividend TTM	-	EV/Sales	13.08	EPS Y/Y TTM	-28.77%	Oper. Margin	-16.62%	ATR (14)	9.29	Perf 10Y	2846.14%
Dividend Ex-Date	-	Quick Ratio	3.13	Sales Y/Y TTM	38.17%	Profit Margin	-14.61%	RSI (14)	35.36	Recom	1.43
Dividend Gr. 3/5Y	- -	Current Ratio	3.27	EPS Q/Q	-150.04%	SMA20	-8.07%	Beta	1.65	Target Price	258.90
Payout	-	Debt/Eq	0.16	Sales Q/Q	34.66%	SMA50	-10.70%	Rel Volume	0.61	Prev Close	207.84
Employees	4434	LT Debt/Eq	0.08	Earnings	Nov 06 AMC	SMA200	11.18%	Avg Volume	1.29M	Price	206.23
IPO	Jul 02, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-65.93% 15.33%	Trades		Volume	790,438	Change	-0.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-07-26	Initiated	Citigroup	Buy	$300
Dec-02-25	Resumed	Morgan Stanley	Overweight	$265
Oct-27-25	Upgrade	BNP Paribas Exane	Underperform → Neutral	$172
Sep-22-25	Resumed	Wells Fargo	Equal Weight	$175
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90

Show Previous Ratings

Feb-12-26 07:27AM	Surgery Partners (SGRY) Moves 7.7% Higher: Will This Strength Last? (Zacks)
Feb-11-26 09:56AM	EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus (Zacks)
Feb-10-26 07:40AM	CVS Health (CVS) Tops Q4 Earnings and Revenue Estimates (Zacks)
Feb-06-26 06:00AM	Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes (Business Wire)
Feb-03-26 05:15PM	InnovAge Holding Corp. (INNV) Q2 Earnings and Revenues Surpass Estimates (Zacks) -9.69%
10:29AM	Loading…
10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 06:00AM	Natera Submits Signatera CDx PMA to FDA (Business Wire)
Jan-29-26 07:29AM	Natera, Inc. (NTRA) Reports Preliminary Q4 Revenue (Insider Monkey)
Jan-26-26 06:00AM	Prospera Featured in Landmark Interventional Study Advancing Lung Transplant Care (Business Wire)
Jan-25-26 11:38PM	2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds (StockStory)
Jan-23-26 10:53AM	Lack of Natera (NTRA) Exposure Weighs on Mid-Cap Fund Performance (Insider Monkey)
Jan-21-26 06:00AM	Natera Publishes Clinical Validation of Latitude Tissue-Free MRD Test in Colorectal Cancer (Business Wire)
Jan-20-26 06:00AM	Natera's Fetal Focus Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting (Business Wire)
Jan-13-26 10:45AM	NTRA & NVDA Partner to Improve AI Models for Precision Medicine (Zacks)
08:00AM	Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling (Business Wire)
10:00AM	Loading…
Jan-12-26 10:00AM	Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA (Business Wire)
Jan-11-26 10:48PM	Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera Growth (Business Wire)
Jan-08-26 08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks) -5.83%
Jan-07-26 02:11PM	Trade Tracker: Stephanie Link sells Eaton and buys more Zoetis, Natera (CNBC TV)
09:41AM	Wayfair upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly)
08:04AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: Applied Digital, BigBear.ai, Block, Deckers Outdoors, GitLab, Hershey, McDonalds, Moderna, and More (24/7 Wall St.)
08:00AM	Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer (Business Wire)
Jan-05-26 07:25PM	Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI (Business Wire)
07:00AM	Natera Launches 21-Gene Fetal Focus Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP Technology (Business Wire)
Dec-31-25 11:56AM	Natera (NTRA) Announces Publication of Findings from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study (Insider Monkey)
Dec-30-25 02:16PM	Medical Stock Hovers Near Buy Point After 46% Gain (Investor's Business Daily)
Dec-26-25 03:40PM	Medical Stocks On The Move In Top Growth List As Health Sector Performance Brightens (Investor's Business Daily)
Dec-23-25 11:03PM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Dec-22-25 10:19PM	J.P. Morgan Lifts Natera, Inc. (NTRA) Target on Signatera Momentum (Insider Monkey)
08:00AM	Natera to Participate in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
08:00AM	Loading…
Dec-18-25 08:00AM	Natera Announces Publication of Signatera Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer (Business Wire)
Dec-12-25 08:00AM	Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer (Business Wire)
Dec-11-25 10:11AM	Crypto Market 2026 Predictions: Which Coins Will 10x and Which Will Crash? (24/7 Wall St.)
10:11AM	Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks (24/7 Wall St.)
Dec-10-25 07:57PM	Phase III PALLAS Study Shows Signatera MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer (Business Wire)
06:15AM	Natera acquires Foresight Diagnostics for up to $450M (MedTech Dive)
Dec-09-25 08:00AM	Natera Highlights New Findings in Lymphoma at the ASH Annual Meeting (Business Wire)
Dec-08-25 04:46AM	Natera purchases Foresight Diagnostics (Medical Device Network)
Dec-05-25 07:00AM	Natera Acquires Foresight Diagnostics (Business Wire)
Dec-03-25 08:00AM	New Signatera Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting (Business Wire)
Dec-02-25 08:00AM	Natera to Present 12 Datasets Including >50,000 Patients Featuring Signatera at the San Antonio Breast Cancer Symposium (Business Wire)
Nov-30-25 03:14AM	30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks (Motley Fool)
Nov-24-25 07:00PM	Natera, GoodRx, and Bio-Techne Shares Are Soaring, What You Need To Know (StockStory)
12:38PM	This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks Hes Buying Now. (24/7 Wall St.)
Nov-21-25 06:55PM	Natera, Amneal, Chemed, The Pennant Group, and HCA Healthcare Shares Are Soaring, What You Need To Know (StockStory)
Nov-20-25 01:25PM	Cathie Wood Targets New Tech Winners, Dumps AMD in Major Shuffle (GuruFocus.com)
Nov-19-25 10:40PM	Spotting Winners: Natera (NASDAQ:NTRA) And Immuno-Oncology Stocks In Q3 (StockStory)
08:00AM	Employees Volunteer Over 1,500 Hours During Natera's Annual Volunteer Month (Business Wire)
Nov-18-25 04:45AM	TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating (Insider Monkey)
Nov-14-25 03:05PM	Stanley Druckenmiller's Strategic Moves: Exiting Philip Morris International Inc with a -3. ... (GuruFocus.com)
07:58AM	Does Natera (NTRA) Have a Long Runway For Growth? (Insider Monkey)
Nov-12-25 08:00AM	Natera Integrates with Flatiron Health's OncoEMR Platform (Business Wire)
Nov-11-25 11:39PM	1 Healthcare Stock with Impressive Fundamentals and 2 Facing Headwinds (StockStory)
Nov-07-25 09:27AM	NTRA Q3 Deep Dive: Oncology Momentum and New Product Expansion Drive Guidance Increase (StockStory)
12:03AM	Natera Inc (NTRA) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions (GuruFocus.com)
Nov-06-25 07:30PM	Here's What Key Metrics Tell Us About Natera (NTRA) Q3 Earnings (Zacks)
05:50PM	Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:02PM	Natera (NASDAQ:NTRA) Delivers Impressive Q3 (StockStory)
04:46PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-04-25 10:19PM	Natera (NTRA) Reports Earnings Tomorrow: What To Expect (StockStory)
Oct-31-25 07:00AM	Natera Announces Expansion to 20 Genes for its Fetal Focus Single-Gene NIPT (Business Wire)
Oct-30-25 07:00AM	Natera to Report its Third Quarter Results on November 6, 2025 (Business Wire)
Oct-28-25 07:00AM	Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity (Business Wire)
Oct-27-25 06:20AM	Halper Sadeh LLC Encourages Natera Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 11:31PM	Reflecting On Immuno-Oncology Stocks' Q2 Earnings: Natera (NASDAQ:NTRA) (StockStory)
01:35PM	Why Are Natera (NTRA) Shares Soaring Today (StockStory)
01:05AM	Successful IMvigor011 Trial Achieves 41% Improvement in Overall Survival for Bladder Cancer Patients (Business Wire)
Oct-16-25 08:00AM	Natera Named to Fast Company's Next Big Things in Tech List (Business Wire)
Oct-13-25 09:28AM	Natera Signatera Validation Study Published in JCO PO Shows Superior Prognostic Value in Testicular Cancer (Insider Monkey)
08:00AM	Natera to Host Investor Call on October 23, 2025 to Discuss ESMO Findings (Business Wire)
Oct-12-25 06:10PM	Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium (Business Wire)
Oct-06-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Sep-30-25 08:00AM	Natera Announces Publication of Signatera Validation Study in Testicular Cancer (Business Wire)
Sep-29-25 08:00AM	Signatera Surveillance Testing Identified 100% of Uterine Cancer Recurrences in Advance of Imaging, New Study Shows (Business Wire)
12:36AM	2 Safe-and-Steady Stocks to Target This Week and 1 Facing Headwinds (StockStory)
Sep-24-25 04:05PM	Why Natera (NTRA) Stock Is Down Today (StockStory) -5.16%
Sep-23-25 01:13PM	Biotech Stocks Rally. 3 Favorite Plays From the Charts. (Barrons.com)
Sep-22-25 09:35AM	Humana initiated, Paycom upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 04:01PM	Why Natera (NTRA) Stock Is Trading Lower Today (StockStory)
Sep-10-25 03:11PM	Why Natera (NTRA) Shares Are Falling Today (StockStory)
12:02AM	3 Reasons We're Fans of Natera (NTRA) (StockStory)
Sep-02-25 01:04AM	Natera (NTRA) Provides an Update on its Intellectual Property Litigation With NeoGenomics (Insider Monkey)
Aug-29-25 05:05PM	Health Care Roundup: Market Talk (The Wall Street Journal)
01:46PM	Why Natera (NTRA) Stock Is Down Today (StockStory)
01:04PM	NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims (Benzinga)
08:18AM	Natera Provides Update on Patent Litigation with NeoGenomics (Business Wire)
04:46AM	Nateras Signatera test to be used in Phase III bladder cancer trial (Medical Device Network)
Aug-28-25 03:56PM	Why Natera (NTRA) Stock Is Up Today (StockStory)
08:00AM	Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer (Business Wire)
Aug-25-25 12:52PM	Natera Shares Rise on the Launch of AI Platform for Precision Oncology (Zacks)
08:00AM	Natera to Present Signatera Data at the IASLC World Conference on Lung Cancer (Business Wire)
Aug-22-25 06:04AM	Natera Technology Featured in 300+ Peer-Reviewed Publications, Underscoring Scientific Leadership in Precision Medicine (Business Wire)
05:00AM	Natera Launches Proprietary AI Foundation Models to Accelerate Diagnostic and Therapeutic Innovation (Business Wire)
12:40AM	1 Healthcare Stock to Own for Decades and 2 We Find Risky (StockStory)
Aug-18-25 12:33PM	Natera pursues ctDNA assay approval after Phase III victory (Clinical Trials Arena)
06:00AM	IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera Strongly Predicting Adjuvant Immunotherapy Benefit (Business Wire)
Aug-15-25 07:15PM	Stanley Druckenmiller's Strategic Moves: Significant Reduction in Coupang Inc. by 3.73% (GuruFocus.com)
Aug-14-25 06:06PM	Liberty All-Star® Growth Fund, Inc. July 2025 Monthly Update (Business Wire)
01:41AM	5 Revealing Analyst Questions From Natera's Q2 Earnings Call (StockStory)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 02 '26	Sale	231.44	3,000	694,309	139,486	Feb 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 03 '26	Sale	230.77	1,639	378,229	137,847	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 02 '26	Sale	230.72	85,299	19,680,040	127,881	Feb 04 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Feb 03 '26	Sale	230.77	4,725	1,090,379	123,156	Feb 04 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	227.83	6,939	1,580,926	52,120	Feb 04 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 03 '26	Sale	231.02	3,594	830,279	178,081	Feb 04 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 03 '26	Sale	230.77	435	100,384	263,161	Feb 04 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Feb 03 '26	Sale	230.77	1,334	307,845	223,813	Feb 04 09:05 PM
MICHAEL BROPHY	Officer	Feb 03 '26	Proposed Sale	231.10	5,671	1,310,568		Feb 03 04:32 PM
STEVEN L CHAPMAN	Officer	Feb 02 '26	Proposed Sale	230.72	85,299	19,679,799		Feb 02 04:58 PM
SOLOMON MOSHKEVICH	Officer	Feb 02 '26	Proposed Sale	231.44	3,000	694,309		Feb 02 04:12 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 28 '26	Sale	237.66	3,648	866,992	213,180	Jan 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 27 '26	Sale	240.53	2,322	558,514	216,828	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 28 '26	Sale	237.56	2,413	573,221	60,926	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '26	Sale	230.40	1,867	430,156	59,059	Jan 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '26	Sale	240.53	784	188,577	63,339	Jan 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 27 '26	Sale	240.53	291	69,995	263,787	Jan 29 08:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 28 '26	Sale	237.66	191	45,394	263,596	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 28 '26	Sale	237.66	1,000	237,662	225,147	Jan 29 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 27 '26	Sale	240.53	886	213,111	226,147	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 28 '26	Sale	237.66	1,200	285,195	142,486	Jan 29 08:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 27 '26	Sale	240.53	1,013	243,658	143,686	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 28 '26	Sale	237.66	928	220,551	175,540	Jan 29 08:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 27 '26	Sale	240.53	784	188,577	176,468	Jan 29 08:35 PM
MICHAEL BROPHY	Officer	Jan 29 '26	Proposed Sale	235.93	1,867	440,481		Jan 29 04:10 PM
MICHAEL BROPHY	Officer	Jan 28 '26	Proposed Sale	240.34	1,176	282,640		Jan 28 04:19 PM
Sheena Jonathan	CO-FOUNDER	Jan 23 '26	Sale	243.94	1,500	365,914	21,782	Jan 27 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 20 '26	Sale	234.74	71,932	16,885,203	217,354	Jan 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 21 '26	Sale	235.00	1,590	373,650	219,150	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 21 '26	Sale	242.54	37,175	9,016,585	64,123	Jan 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 20 '26	Sale	234.74	23,948	5,621,515	99,776	Jan 22 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 21 '26	Sale	234.46	3,163	741,612	264,078	Jan 22 09:05 PM
Sheena Jonathan	CO-FOUNDER	Jan 20 '26	Sale	234.74	2,981	699,755	267,050	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 20 '26	Sale	234.74	19,234	4,514,958	226,615	Jan 22 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 21 '26	Sale	235.00	438	102,930	227,033	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 20 '26	Sale	234.74	23,205	5,447,105	144,992	Jan 22 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 21 '26	Sale	235.00	293	68,855	144,699	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 20 '26	Sale	234.74	17,806	4,179,752	177,591	Jan 22 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 21 '26	Sale	235.00	339	79,665	177,252	Jan 22 09:05 PM
MICHAEL BROPHY	Officer	Jan 21 '26	Proposed Sale	234.85	36,573	8,589,169		Jan 21 04:54 PM
Sheena Jonathan	CO-FOUNDER	Jan 05 '26	Option Exercise	9.59	39,615	379,908	262,581	Jan 06 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 02 '26	Sale	228.95	2,951	675,621	123,499	Jan 06 09:05 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 02 '26	Sale	229.08	3,848	881,482	136,568	Jan 06 09:05 PM
SOLOMON MOSHKEVICH	Officer	Jan 02 '26	Proposed Sale	228.95	2,951	675,621		Jan 02 04:13 PM
STEVEN L CHAPMAN	Officer	Jan 02 '26	Proposed Sale	229.08	3,848	881,482		Jan 02 04:13 PM
Sheena Jonathan	CO-FOUNDER	Dec 19 '25	Sale	225.94	1,500	338,914	22,532	Dec 22 08:05 PM
Sheena Jonathan	Director	Dec 19 '25	Proposed Sale	220.00	4,500	990,000		Dec 19 10:03 AM
Sheena Jonathan	CO-FOUNDER	Dec 17 '25	Sale	227.01	3,070	696,912	222,966	Dec 17 08:35 PM
Sheena Jonathan	Director	Dec 17 '25	Proposed Sale	228.00	9,210	2,099,880		Dec 17 11:44 AM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Option Exercise	9.59	22,376	214,586	126,565	Dec 16 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 12 '25	Sale	230.76	4,692	1,082,714	113,065	Dec 16 09:05 PM
ROSENMAN HERM	Director	Dec 12 '25	Sale	227.42	48,419	11,011,477	20,342	Dec 16 09:05 PM
SOLOMON MOSHKEVICH	Officer	Dec 12 '25	Proposed Sale	230.76	4,692	1,082,714		Dec 12 05:17 PM
Herm Rosenman Trust	Board member	Dec 12 '25	Proposed Sale	233.13	48,419	11,287,921		Dec 12 10:07 AM
Sheena Jonathan	CO-FOUNDER	Dec 09 '25	Option Exercise	9.29	4,436	41,210	227,096	Dec 11 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Option Exercise	32.15	4,000	128,600	10,143	Dec 09 08:35 PM
Chapman Rowan E	Director	Dec 05 '25	Sale	243.10	4,366	1,061,389	5,777	Dec 09 08:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Dec 04 '25	Option Exercise	19.68	6,902	135,831	208,601	Dec 08 09:55 PM
ROWAN EMMA CHAPMAN	Director	Dec 05 '25	Proposed Sale	243.10	4,366	1,061,391		Dec 05 07:25 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 01 '25	Sale	238.15	3,000	714,459	109,061	Dec 03 08:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Dec 01 '25	Sale	238.07	4,400	1,047,502	140,416	Dec 03 08:35 PM
STEVEN L CHAPMAN	Officer	Dec 01 '25	Proposed Sale	238.07	4,400	1,047,501		Dec 01 04:10 PM
SOLOMON MOSHKEVICH	Officer	Dec 01 '25	Proposed Sale	238.15	3,000	714,459		Dec 01 04:08 PM
BOTHA ROELOF	Director	Nov 24 '25	Sale	236.12	75,000	17,708,936	1,154,198	Nov 26 05:00 PM
BV369 TRUST	Affiliate	Nov 24 '25	Proposed Sale	236.12	75,000	17,709,000		Nov 24 04:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 20 '25	Sale	225.08	10,000	2,250,816	222,660	Nov 21 08:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 21 '25	Sale	230.01	4,000	920,030	23,282	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Option Exercise	41.17	7,668	315,689	26,027	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Option Exercise	40.93	5,112	209,234	23,471	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 20 '25	Sale	223.08	7,668	1,710,600	18,359	Nov 21 08:05 PM
Baynes Roy D.	Director	Nov 19 '25	Sale	215.00	5,112	1,099,088	18,359	Nov 21 08:05 PM
ROY BAYNES	Director	Nov 20 '25	Proposed Sale	223.08	7,668	1,710,600		Nov 20 04:03 PM
Sheena Jonathan	Director	Nov 20 '25	Proposed Sale	225.02	10,000	2,250,186		Nov 20 11:21 AM
ROY BAYNES	Director	Nov 19 '25	Proposed Sale	215.00	5,112	1,099,088		Nov 19 04:04 PM
Sheena Jonathan	CO-FOUNDER	Nov 07 '25	Sale	192.56	3,070	591,159	232,660	Nov 12 08:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 11 '25	Sale	207.96	1,500	311,934	25,282	Nov 12 08:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 04 '25	Sale	200.51	22,900	4,591,674	2,280,852	Nov 04 09:35 PM
Sheena Jonathan	CO-FOUNDER	Nov 03 '25	Sale	200.07	4,000	800,274	26,032	Nov 04 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Nov 03 '25	Sale	198.60	3,000	595,810	112,061	Nov 04 09:35 PM
Marcus Gail Boxer	Director	Nov 03 '25	Sale	198.71	122	24,243	5,762	Nov 04 09:05 PM
MATTHEW RABINOWITZ	Director	Nov 04 '25	Proposed Sale	198.23	22,900	4,539,467		Nov 04 04:33 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Option Exercise	116.02	155,679	18,062,483	305,519	Nov 03 09:40 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 03 '25	Sale	199.96	160,703	32,133,981	144,816	Nov 03 09:40 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 03 '25	Sale	200.00	17,100	3,420,003	2,303,752	Nov 03 09:35 PM
MATTHEW RABINOWITZ	Director	Nov 03 '25	Proposed Sale	198.93	17,100	3,401,703		Nov 03 04:26 PM
SOLOMON MOSHKEVICH	Officer	Nov 03 '25	Proposed Sale	198.60	3,000	595,810		Nov 03 04:07 PM
STEVEN L CHAPMAN	Officer	Nov 03 '25	Proposed Sale	199.96	160,703	32,133,983		Nov 03 04:03 PM
Gail Marcus	Director	Nov 03 '25	Proposed Sale	198.71	122	24,243		Nov 03 01:24 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '25	Sale	191.46	3,680	704,580	149,840	Oct 29 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 27 '25	Sale	192.32	2,335	449,077	153,520	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '25	Sale	191.16	2,415	461,648	65,993	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '25	Sale	190.64	1,867	355,925	64,126	Oct 29 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 27 '25	Sale	192.32	781	150,205	68,408	Oct 29 09:35 PM
Sheena Jonathan	CO-FOUNDER	Oct 27 '25	Sale	192.32	288	55,389	235,921	Oct 29 09:05 PM
Sheena Jonathan	CO-FOUNDER	Oct 28 '25	Sale	191.46	191	36,569	235,730	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '25	Sale	191.46	1,058	202,567	201,699	Oct 29 09:05 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 27 '25	Sale	192.32	935	179,823	202,757	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '25	Sale	191.46	1,198	229,371	115,061	Oct 29 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 27 '25	Sale	192.32	1,008	193,863	116,259	Oct 29 09:05 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '25	Sale	191.46	928	177,677	150,699	Oct 29 09:05 PM

Open in Screener

TVTX

Travere Therapeutics Inc

Feb 13 • 04:00PM ET

27.82

-2.78 -9.08 %

Healthcare • Biotechnology • USA • NASD

TVTX Travere Therapeutics Inc daily Stock Chart

Peers: BMRN RARE SRPT VYGR FOLD QURE CRSP AGIO CLLS PFE

| Held by: VTI XBI IWM VXF IWO IBB VTWO SCHA VHT PJP

Index	RUT	P/E	-	EPS (ttm)	-1.08	Insider Own	2.05%	Shs Outstand	89.46M	Perf Week	-6.36%
Market Cap	2.49B	Forward P/E	32.46	EPS next Y	0.86	Insider Trans	-23.37%	Shs Float	87.64M	Perf Month	-3.84%
Enterprise Value	2.56B	PEG	-	EPS next Q	0.00	Inst Own	117.95%	Short Float	16.54%	Perf Quarter	-23.72%
Income	-88.54M	P/S	5.71	EPS this Y	91.78%	Inst Trans	2.11%	Short Ratio	7.05	Perf Half Y	52.61%
Sales	435.83M	P/B	33.83	EPS next Y	355.59%	ROA	-16.98%	Short Interest	14.49M	Perf YTD	-27.19%
Book/sh	0.82	P/C	9.78	EPS next 5Y	-	ROE	-410.78%	52W High	42.13 -33.97%	Perf Year	17.28%
Cash/sh	2.84	P/FCF	-	EPS past 3/5Y	-10.63% -3.34%	ROIC	-22.27%	52W Low	12.91 115.49%	Perf 3Y	31.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	0.83% 5.87%	Gross Margin	85.08%	Volatility	6.49% 5.68%	Perf 5Y	5.46%
Dividend TTM	-	EV/Sales	5.88	EPS Y/Y TTM	77.02%	Oper. Margin	-20.59%	ATR (14)	1.98	Perf 10Y	98.71%
Dividend Ex-Date	-	Quick Ratio	2.71	Sales Y/Y TTM	114.22%	Profit Margin	-20.32%	RSI (14)	36.26	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	2.75	EPS Q/Q	135.55%	SMA20	-7.63%	Beta	0.81	Target Price	42.29
Payout	-	Debt/Eq	4.48	Sales Q/Q	162.11%	SMA50	-16.26%	Rel Volume	1.49	Prev Close	30.60
Employees	385	LT Debt/Eq	4.40	Earnings	Feb 19 AMC	SMA200	12.77%	Avg Volume	2.06M	Price	27.82
IPO	Oct 06, 2003	Option/Short	Yes / Yes	EPS/Sales Surpr.	192.20% 56.70%	Trades		Volume	3,062,236	Change	-9.08%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-31-25	Reiterated	Citigroup	Buy	$34 → $48
Jun-11-25	Resumed	H.C. Wainwright	Buy	$30
Jun-11-25	Reiterated	Citigroup	Buy	$35 → $32
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$9 → $27
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy	$25
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Nov-20-23	Initiated	Citigroup	Neutral	$7
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$24 → $8
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform	$30
Jul-21-23	Initiated	JP Morgan	Overweight	$26
Jun-07-23	Resumed	Piper Sandler	Neutral	$22
May-22-23	Initiated	TD Cowen	Outperform	$30
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy	$37
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform	$30
Dec-14-22	Initiated	Stifel	Hold	$22

Show Previous Ratings

Feb-12-26 04:30PM	Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results (Business Wire) -9.08%
10:00AM	Travere Therapeutics (TVTX) Earnings Expected to Grow: Should You Buy? (Zacks)
Feb-11-26 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-04-26 04:30PM	Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit (Business Wire) -6.98%
Jan-28-26 05:35PM	Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +5.65%
09:52PM	Loading…
Jan-22-26 09:52PM	BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari (Insider Monkey) +5.24%
Jan-16-26 11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
06:44AM	Travere Stock Slips After FDA Delays Review Of Key Kidney Drug (Benzinga)
Jan-13-26 07:51PM	Why Travere Therapeutics Stock Got Trounced on Tuesday (Motley Fool) -14.63%
04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily)
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
01:24PM	Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire)
11:19AM	Options Bears Eye Plummeting Biotech Stock (Schaeffer's Research)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
09:54AM	Loading…
09:54AM	Travere Therapeutics Hammered On A Potential, Surprise Delay For Filspari (Investor's Business Daily)
Jan-12-26 05:00PM	Travere Therapeutics Provides Corporate Update and 2026 Outlook (Business Wire)
Jan-05-26 04:30PM	Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire) -6.06%
Dec-25-25 10:44AM	Dow Jones, S&P 500 Hit Record Highs. Stock Market Closed For Christmas. (Investor's Business Daily)
Dec-24-25 06:51PM	Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday (Motley Fool) +13.91%
04:40PM	Nvidia Buying AI Chip Startup Groq In Record $20 Billion Deal: CNBC (Investor's Business Daily)
01:40PM	Dow Jones, S&P 500 Hit Record Highs Heading Into Christmas Holiday (Investor's Business Daily)
Dec-18-25 10:41AM	Will Strong Livmarli Uptake Continue to Aid MIRM's Revenues in 2026? (Zacks)
Dec-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-26-25 08:00AM	Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 (Investor's Business Daily)
Nov-10-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.31% +5.03%
Nov-06-25 11:00AM	Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Nov-04-25 05:23PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
Nov-03-25 01:34AM	Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings (Insider Monkey)
Nov-01-25 02:48PM	Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook (Insider Monkey)
07:35PM	Loading…
Oct-31-25 07:35PM	Closing Bell Movers: Amazon soars to all-time highs on earnings (TipRanks) +18.58%
04:06PM	Top 2% Travere Catapults To Profit-Taking Zone After Screaming Up Another Beat (Investor's Business Daily)
Oct-30-25 11:02PM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Call Highlights: Strong FILSPARI Sales and ... (GuruFocus.com)
06:30PM	Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:51PM	Travere: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Third Quarter 2025 Financial Results (Business Wire)
Oct-29-25 09:41AM	Travere Therapeutics Inc (TVTX) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-27-25 06:58AM	Chugai acquires Renalys, enhancing its kidney disease portfolio (Pharmaceutical Technology) +6.09%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-23-25 04:30PM	Travere Therapeutics to Report Third Quarter 2025 Financial Results (Business Wire)
12:22PM	Biotech Leader Travere Therapeutics Eyes Buy Point After More Than Doubling (Investor's Business Daily)
Oct-17-25 09:01AM	Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 (Business Wire)
Oct-16-25 08:50AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug (Zacks)
Oct-15-25 12:00PM	What Makes Travere (TVTX) a New Strong Buy Stock (Zacks)
Oct-14-25 10:56AM	Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings? (Zacks)
Oct-10-25 05:11PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-26-25 07:00AM	CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy (Business Wire)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly)
Sep-12-25 01:16PM	Hims & Hers Leads 14 Growth Stocks Amid Medical Boom (Investor's Business Daily) -6.12%
Sep-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.46%
10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
09:15AM	Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside (Insider Monkey)
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 11:17AM	Stock Market Today: Inflation Data Hits Dow; Oracle Soars As This Biotech Zooms (Live Coverage) (Investor's Business Daily) +26.20%
09:13AM	Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High (Investor's Business Daily)
07:01AM	Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI (sparsentan) in FSGS (Business Wire)
Sep-03-25 07:01AM	Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism (Business Wire) +8.04%
Aug-28-25 10:00AM	Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch (Investor's Business Daily)
Aug-27-25 05:09PM	Travere Therapeutics Announces U.S. FDA Approves REMS Modification for FILSPARI (sparsentan) in IgA Nephropathy (Business Wire)
Aug-17-25 11:41PM	Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts (Insider Monkey)
Aug-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-08-25 09:06AM	Travere Therapeutics price target raised to $32 from $30 at Wedbush (TipRanks)
Aug-06-25 06:00PM	Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Travere: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Travere Therapeutics Reports Second Quarter 2025 Financial Results (Business Wire)
Aug-05-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
09:54AM	Earnings To Watch: Travere Therapeutics Inc (TVTX) Reports Q2 2025 Result (GuruFocus.com)
Jul-31-25 10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-30-25 04:30PM	Travere Therapeutics to Report Second Quarter 2025 Financial Results (Business Wire)
Jul-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-06-25 04:15AM	Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX) (Insider Monkey)
Jun-24-25 12:46PM	Travere Therapeutics Kicks Off "Play It Forward" Campaign for FSGS Awareness (Insider Monkey) +5.18%
Jun-13-25 02:02PM	HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs (Insider Monkey)
Jun-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-11-25 07:01AM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the 15th International Podocyte Conference (Business Wire)
Jun-10-25 07:00AM	Travere Therapeutics Launches 'Play It Forward' Campaign to Celebrate the FSGS Community on Inaugural Awareness Day (Business Wire)
Jun-03-25 04:30PM	Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress (Business Wire)
May-23-25 04:00AM	England's NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (PR Newswire)
May-15-25 04:05PM	Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI (sparsentan) in FSGS (Business Wire) -20.57%
May-13-25 04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.59%
May-07-25 04:30PM	Travere Therapeutics to Participate at Upcoming Investor Conferences (Business Wire)
May-01-25 11:07PM	Travere Therapeutics, Inc. (TVTX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	Compared to Estimates, Travere (TVTX) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Travere Therapeutics (TVTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Travere Therapeutics Reports First Quarter 2025 Financial Results (Business Wire)
Apr-29-25 07:01AM	Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy (Business Wire)
02:00AM	CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI in IgA Nephropathy (PR Newswire)
Apr-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.62%
Apr-24-25 04:30PM	Travere Therapeutics to Report First Quarter 2025 Financial Results (Business Wire) +5.57%
Apr-12-25 10:20AM	Travere Therapeutics price target lowered to $30 from $32 at Scotiabank (TipRanks)
Apr-11-25 05:00PM	Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.49%
Apr-07-25 03:27AM	Novavax (NVAX) Soars 11.4%: Is Further Upside Left in the Stock? (Zacks)
Mar-31-25 04:30PM	Travere Therapeutics to Present New FILSPARI (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 (Business Wire) -8.94%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-26-25 09:39PM	Is Travere Therapeutics, Inc. (NASDAQ:TVTX) the Best Small Cap Stock to Buy Before They Explode? (InsiderMonkey)
07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire)

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 04 '26	Sale	32.21	1,779	57,295	105,706	Feb 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 04 '26	Sale	32.19	1,745	56,168	111,226	Feb 05 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 04 '26	Sale	32.18	2,994	96,359	105,211	Feb 05 04:05 PM
ELIZABETH REED	Officer	Feb 04 '26	Proposed Sale	32.18	2,994	96,360		Feb 04 04:07 PM
JULA INRIG	Officer	Feb 04 '26	Proposed Sale	32.21	1,779	57,299		Feb 04 04:06 PM
CHRISTOPHER CLINE	Officer	Feb 04 '26	Proposed Sale	32.19	1,745	56,166		Feb 04 04:01 PM
Peter Heerma	Officer	Feb 03 '26	Proposed Sale	32.12	7,310	234,799		Feb 04 06:00 AM
Elizabeth E. Reed	Officer	Feb 03 '26	Proposed Sale	32.12	7,175	230,464		Feb 03 09:59 PM
Sandra Calvin	Officer	Feb 03 '26	Proposed Sale	32.12	4,333	139,177		Feb 03 09:58 PM
Christopher Cline	Officer	Feb 03 '26	Proposed Sale	32.12	7,242	232,616		Feb 03 09:45 PM
Jula Inrig	Officer	Feb 03 '26	Proposed Sale	32.12	6,956	223,429		Feb 03 09:37 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Feb 03 '26	Sale	32.28	100,087	3,230,316	432,886	Feb 03 09:30 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Feb 03 '26	Sale	32.12	6,956	223,427	107,485	Feb 03 09:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Feb 03 '26	Sale	32.12	7,242	232,613	112,971	Feb 03 09:30 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Feb 03 '26	Sale	32.12	7,310	234,797	131,823	Feb 03 09:30 PM
ROTE WILLIAM E.	Chief Research Officer	Feb 03 '26	Sale	32.87	12,446	409,100	109,087	Feb 03 09:30 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Feb 03 '26	Sale	32.12	4,333	139,176	49,080	Feb 03 09:30 PM
REED ELIZABETH E	Chief Legal Officer and GC	Feb 03 '26	Sale	32.12	7,175	230,461	108,205	Feb 03 09:30 PM
Dube Eric M	Officer	Feb 03 '26	Proposed Sale	32.87	100,087	3,289,860		Feb 03 11:38 AM
ROTE WILLIAM E.	Officer	Feb 03 '26	Proposed Sale	32.87	12,446	409,100		Feb 03 10:05 AM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Option Exercise	15.46	51,865	801,833	471,038	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Option Exercise	15.46	8,135	125,767	427,308	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 27 '26	Sale	30.10	51,865	1,560,981	419,173	Jan 27 08:25 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Jan 23 '26	Sale	30.01	8,135	244,153	419,173	Jan 27 08:25 PM
Dube Eric M	Officer	Jan 27 '26	Proposed Sale	30.10	51,865	1,560,982		Jan 27 04:05 PM
Dube Eric M	Officer	Jan 23 '26	Proposed Sale	30.01	8,135	244,153		Jan 23 04:14 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Option Exercise	19.08	10,000	190,800	100,270	Jan 21 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Jan 20 '26	Sale	27.34	10,000	273,420	90,270	Jan 21 04:05 PM
ELIZABETH REED	Officer	Jan 20 '26	Proposed Sale	27.34	10,000	273,420		Jan 20 04:04 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 05 '26	Sale	40.18	2,031	81,606	86,756	Jan 07 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jan 06 '26	Sale	37.75	445	16,799	86,311	Jan 07 04:05 PM
JULA INRIG	Officer	Jan 06 '26	Proposed Sale	37.75	445	16,799		Jan 06 04:07 PM
Jula Inrig	Officer	Jan 05 '26	Proposed Sale	40.18	2,031	81,606		Jan 05 07:49 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Dec 24 '25	Sale	40.00	4,980	199,200	113,013	Dec 29 09:11 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Option Exercise	20.61	60,000	1,236,600	161,443	Dec 29 09:05 PM
ROTE WILLIAM E.	Chief Research Officer	Dec 24 '25	Sale	40.10	60,000	2,406,180	101,443	Dec 29 09:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Option Exercise	8.93	15,000	133,950	103,787	Dec 29 09:01 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Dec 24 '25	Sale	42.00	15,000	630,004	88,787	Dec 29 09:01 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 24 '25	Sale	40.00	7,402	296,080	38,233	Dec 29 08:59 PM
JULA INRIG	Officer	Dec 24 '25	Proposed Sale	42.00	15,000	630,004		Dec 29 09:39 AM
SANDRA CALVIN	Officer	Dec 24 '25	Proposed Sale	40.00	7,402	296,080		Dec 29 09:38 AM
Heerma Peter	Officer	Dec 24 '25	Proposed Sale	40.00	4,980	199,200		Dec 29 06:58 AM
ROTE WILLIAM E.	Officer	Dec 24 '25	Proposed Sale	40.10	60,000	2,406,179		Dec 29 06:28 AM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Dec 15 '25	Sale	36.00	2,910	104,760	45,635	Dec 16 04:23 PM
SANDRA CALVIN	Officer	Dec 15 '25	Proposed Sale	36.00	2,910	104,760		Dec 15 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Option Exercise	16.23	20,000	324,600	112,083	Dec 03 04:30 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Dec 01 '25	Sale	35.01	20,000	700,202	92,083	Dec 03 04:30 PM
CHRISTOPHER CLINE	Officer	Dec 01 '25	Proposed Sale	35.01	20,000	700,200		Dec 01 04:09 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Option Exercise	24.02	61,250	1,471,212	115,660	Nov 06 04:05 PM
Calvin Sandra	SVP, CHIEF ACCOUNTING OFFICER	Nov 04 '25	Sale	36.00	67,115	2,416,140	48,545	Nov 06 04:05 PM
SANDRA CALVIN	Officer	Nov 04 '25	Proposed Sale	36.00	67,115	2,416,140		Nov 04 04:14 PM
Coughlin Timothy	Director	Oct 31 '25	Option Exercise	16.95	18,000	305,040	73,500	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Sale	35.03	18,000	630,601	55,500	Nov 04 04:05 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 31 '25	Sale	35.00	5,591	195,685	119,071	Nov 04 04:05 PM
Coughlin Timothy	Director	Oct 31 '25	Proposed Sale	34.98	18,000	629,693		Oct 31 04:05 PM
Heerma Peter	Officer	Oct 31 '25	Proposed Sale	35.00	5,591	195,685		Oct 31 02:51 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Option Exercise	15.46	92,872	1,435,801	512,045	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Option Exercise	15.46	27,128	419,399	446,301	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 28 '25	Sale	30.38	92,872	2,821,358	419,173	Oct 30 04:45 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	Oct 29 '25	Sale	30.12	27,128	817,074	419,173	Oct 30 04:45 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	Oct 28 '25	Sale	30.00	2,662	79,860	124,662	Oct 30 04:45 PM
Dube Eric M	Officer	Oct 29 '25	Proposed Sale	30.12	27,128	817,045		Oct 29 04:26 PM
Dube Eric M	Officer	Oct 28 '25	Proposed Sale	30.38	92,872	2,821,217		Oct 28 04:57 PM
Heerma Peter	Officer	Oct 28 '25	Proposed Sale	30.00	2,662	79,860		Oct 28 02:08 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Option Exercise	19.08	10,000	190,800	99,878	Sep 24 04:05 PM
REED ELIZABETH E	Chief Legal Officer and GC	Sep 22 '25	Sale	25.00	10,000	250,000	89,878	Sep 24 04:05 PM
ELIZABETH REED	Officer	Sep 22 '25	Proposed Sale	25.00	10,000	250,000		Sep 22 04:02 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 03 '25	Sale	18.20	454	8,263	92,202	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Sep 04 '25	Sale	19.71	119	2,345	92,083	Sep 05 04:05 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Aug 27 '25	Sale	17.31	470	8,136	92,656	Aug 28 04:05 PM
Inrig Jula	CHIEF MEDICAL OFFICER	Jul 01 '25	Sale	14.65	815	11,940	88,787	Jul 02 05:28 PM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	May 05 '25	Sale	21.05	1,784	37,553	93,126	May 05 09:54 PM
Dube Eric M	CHIEF EXECUTIVE OFFICER	May 05 '25	Sale	21.05	18,924	398,350	419,173	May 05 09:53 PM
Heerma Peter	CHIEF COMMERCIAL OFFICER	May 05 '25	Sale	21.05	1,771	37,280	128,215	May 05 09:53 PM
ROTE WILLIAM E.	Chief Research Officer	May 05 '25	Sale	21.05	3,198	67,318	100,241	May 05 09:52 PM
REED ELIZABETH E	Chief Legal Officer and GC	May 05 '25	Sale	21.05	4,920	103,566	89,482	May 05 09:51 PM
Christopher Cline	Officer	May 05 '25	Proposed Sale	21.05	1,784	37,553		May 05 07:45 PM
Peter Heerma	Officer	May 05 '25	Proposed Sale	21.05	1,771	37,280		May 05 07:41 PM
REED ELIZABETH E	Officer	May 05 '25	Proposed Sale	21.05	4,920	103,566		May 05 11:32 AM
Dube Eric M	Officer	May 05 '25	Proposed Sale	21.05	18,924	398,350		May 05 11:20 AM
ROTE WILLIAM E.	Officer	May 05 '25	Proposed Sale	21.05	3,198	67,318		May 05 10:08 AM
Cline Christopher R.	CHIEF FINANCIAL OFFICER	Apr 11 '25	Sale	13.14	48	631	89,990	Apr 14 06:23 PM
Christopher Cline	Officer	Apr 11 '25	Proposed Sale	13.14	48	631		Apr 11 07:03 PM

NTRA

Natera Inc

TVTX

Travere Therapeutics Inc

Upgrade your FINVIZ experience